Increased production of tumor necrosis factor α, and not of interferon γ, preceding disease activity in patients with multiple sclerosis

Archives of Neurology

Volumn 55, Issue 6, 1998, Pages 793-798

  Van Oosten, Bob W ^a   Barkhof, Frederik ^a   Scholten, Petra E T ^a   Von Blomberg, B Mary E ^a   Adèr, Herman J ^b   Polman, Chris H ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; OKT 4; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL EXAMINATION; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HUMAN; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

ADULT; BIOLOGICAL MARKERS; DISEASE PROGRESSION; FEMALE; HUMANS; INTERFERON TYPE II; MAGNETIC RESONANCE IMAGING; MALE; MULTIPLE SCLEROSIS; PROSPECTIVE STUDIES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0031780251     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.55.6.793     Document Type: Article

References (42)

1. Traugott U, Reinherz EL, Raine CS. Multiple sclerosis: distribution of T-cell subsets within active chronic lesions. Science. 1982;219:308-310.
2. Traugott U. Multiple sclerosis: relevance of class I and class II MHC-expressing cells to lesion development. J Neuroimmunol. 1987;16:283-302.
3. Hayashi T, Morimoto C, Burks JS, Kerr C, Hauser SL. Dual label immunocyto-chemistry of the active multiple sclerosis lesion: major histocompatibility complex and activation antigens. Ann Neurol. 1988;24:523-531.
4. Kennedy MK, Torrance DS, Picha KS, Mohler KM. Analysis of cytokine mRNA expression in the central nervous system of mice with experimental autoimmune encephalomyelitis reveals that IL-10 mRNA expression correlates with recovery. J Immunol. 1992;149:2496-2505.
5. Issazadeh S, Mustafa M, Ljungdahl Å, et al. Interferon gamma, interleukin 4 and transforming growth factor beta in experimental autoimmune encephalomyelitis in Lewis rats: dynamics of cellular mRNA expression in the central nervous system and lymphoid cells. J Neurosci Res. 1995;40:579-590.
6. Selmaj K, Raine CS, Cannella B, Brosnan CF. Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. J Clin Invest. 1991;87:949-954.
7. Cannella B, Raine CS. The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann Neurol. 1995;37:424-435.
8. Rieckmann P, Albrecht M, Kitze B, et al. Cytokine mRNA levels in mono-nuclear blood cells from patients with multiple sclerosis. Neurology. 1994;44: 1523-1526.
9. Rieckmann P, Albrecht M, Kitze B, et al. Tumor necrosis factor-alpha messenger RNA expression in patients with relapsing-remitting multiple sclerosis is associated with disease activity. Ann Neurol. 1995;37:82-88.
10. Beck J, Rondot P, Catinot L, Falcoff E, Kirchner H, Wietzerbin J. Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: do cytokines trigger off exacerbations? Acta Neurol Scand. 1988;78:318-323.
11. Chofflon M, Juillard C, Juillard P, Gauthier G, Grau GE. Tumor necrosis factor alpha production as a possible predictor of relapse in patients with multiple sclerosis. Eur Cytokine Netw. 1992;3:523-531.
12. Philippé J. Debruyne J, Leroux-Roels G, Willems A, Dereuck J. In vitro TNF-alpha, IL-2 and IFN-gamma production as markers of relapses in multiple sclerosis. Clin Neurol Neurosurg. 1996;98:286-290.
13. Imamura K, Suzumura A, Hayashi F, Marunouchi T. Cytokine production by peripheral blood monocytes/macrophages in multiple sclerosis patients. Acta Neurol Scand. 1993;87:281-285.
14. Sharief MK, Hentges R. Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis. N Engl J Med. 1991;325: 467-472.
15. Tsukada N, Miyagi K, Matsuda M, Yanagisawa N, Yone K. Tumor necrosis factor and interleukin-1 in the CSF and sera of patients with multiple sclerosis. J Neurol Sci. 1991;102:230-234.
16. Matsuda M, Tsukada N, Miyagi K, Yanagisawa N. Increased levels of soluble tumor necrosis factor receptor in patients with multiple sclerosis and HTLV-1-associated myelopathy. J Neuroimmunol. 1994;52:33-40.
17. Franciotta DM, Grimaldi LME, Martino GV, et al. Tumor necrosis factor in serum and cerebrospinal fluid of patients with multiple sclerosis. Ann Neurol. 1989;26: 787-789.
18. Hauser SL, Doolittle TH, Lincoln R, Brown RH, Dinarello CA. Cytokine accumulations in CSF of multiple sclerosis patients: frequent detection of interleukin-1 and tumor necrosis factor but not interleukin-6. Neurology. 1990;40:1735-1739.
19. Gallo P, Piccino MG, Krzalic L, Tavolato B. Tumor necrosis factor alpha (TNF-alpha) and neurological diseases: failure in detecting TNF-alpha in the cerebrospinal fluid from patients with multiple sclerosis, AIDS dementia complex, and brain tumours. J Neuroimmunol. 1989;23:41-44.
20. Peter JB, Boctor FN, Tourtelotte WW. Serum and CSF levels of IL-2, sIL-2R, TNF-alpha, and IL-1ß in chronic progressive multiple sclerosis: expected lack of clinical utility. Neurology. 1991;41:121-123.
21. van Oosten BW, Rep MHG, van Lier RAW, et al. A pilot study investigating the effects of orally administered pentoxifylline on selected immune variables in patients with multiple sclerosis. J Neuroimmunol. 1996;66:49-55.
22. Correale J, Gilmore W, McMillan M, et al. Patterns of cytokine secretion by autoreactive proteolipid protein-specific T cell clones during the course of multiple sclerosis. J Immunol. 1995;154:2959-2968.
23. Salmaggi A, Dufour A, Eoli M, et al. Low serum interleukin-10 levels in multiple sclerosis: further evidence for decreased systemic immunosuppression? J Neurol. 1996;243:13-17.
24. Westendorp RGJ, Langermans JAM, Huizinga TWL, et al. Genetic influence on cytokine production and fatal meningococcal disease. Lancet. 1997;349: 170-173.
25. Zipp F, Weber F, Huber S, et al. Genetic control of multiple sclerosis: increased production of lymphotoxin and TNF-alpha by HLA-DR2+ T-cells. Ann Neurol. 1995; 38:723-730.
26. Harris JO, Frank JA, Patronas N, McFarlin DE, McFarland HF. Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early relapsing-remitting multiple sclerosis: implications for clinical trials and natural history. Ann Neurol. 1991;29:548-555.
27. Barkhof F, Scheltens P, Frequin P, et al. Relapsing-remitting multiple sclerosis: sequential enhanced MR imaging vs clinical findings in determining disease activity. Am J Radiol. 1992;159:1041-1047.
28. Thompson AJ, Miller D, Youl B, et al. Serial gadolinium-enhanced MRI in relapsing/ remitting multiple sclerosis of varying disease duration. Neurology. 1992;42: 60-63.
29. Spuler S, Yousry T, Scheller A, et al. Multiple sclerosis: prospective analysis of TNF-alpha and 55 kDa TNF receptor in CSF and serum in correlation with clinical and MRI activity. J Neuroimmunol. 1996;66:57-64.
30. van Oosten BW, Lai M, Hodgkinson S, et al. Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double blind, placebo controlled, MR-monitored phase II trial. Neurology. 1997;49:351-357.
31. Llewellyn-Smith N, Lai M, Miller DH, et al. Effects of anti-CD4 antibody treatment on lymphocyte subsets and stimulated tumor necrosis factor alpha production: a study of 29 multiple sclerosis patients entered into a clinical trial of cM-T412. Neurology. 1997;48:810-816.
32. Rep MHG, van Oosten BW, Roos MTL, et al. Treatment with depleting anti-CD4 monoclonal antibody results in a preferential loss of circulating naive T cells but does not affect IFN-gamma secreting TH1 cells in humans. J Clin Invest. 1997; 99:2225-2231.
33. van Oosten BW, Lai M, Barkhof F, et al. A phase II trial of anti-CD4 antibodies in the treatment of multiple sclerosis. Multiple Sclerosis. 1996;1:339-342.
34. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983;13:227-231.
35. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33:1444-1452.
36. Miller DH, Barkhof F, Berry I, Kappos L, Scotti G, Thompson AJ. Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines. J Neurol Neurosurg Psychiatry. 1991;54:683-688.
37. de Groote D, Zangerle PF, Gevaert Y, et al. Direct stimulation of cytokines (IL-1-beta, TNF-alpha, IL-6, IL-2, IFN-gamma, and GM-CSF) in whole blood, I: comparison with isolated PBMC stimulation. Cytokine. 1992;4:239-249.
38. Panitch HS, Hirsch RL, Schindler J, Johnson KP. Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system. Neurology. 1987;37:1097-1102.
39. IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis, I: clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 1993;43:655-661.
40. Dayal AS, Jensen MA, Lledo A, Arnason BGW. Interferon-gamma-secreting cells in multiple sclerosis patients treated with interferon beta-1b. Neurology. 1995; 45:2173-2177.
41. Krakowski M, Owens T. Interferon-gamma confers resistance to experimental allergic encephalomyelitis. Eur J Immunol. 1996;26:1641-1646.
42. Heremans H, Dillen C, Groenen M, Martens E, Billiau A. Chronic relapsing experimental autoimmune encephalomyelitis (CREAE) in mice: enhancement by monoclonal antibodies against interferon-gamma. Eur J Immunol. 1996;26: 2393-2398.